Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2021

View Archived Issues

Phase III trial investigates TQB-2450 with anlotinib for advanced biliary cancer

Phase II data reported for GV-1001 in moderate to severe Alzheimer's disease

Cancer vaccine VEGFC-Vax induces lymphangiogenesis for melanoma immunotherapy

Study to assess analytical treatment interruption in participants who contracted HIV in VRC-01 trial

CD38 inhibition as a potent new therapeutic approach against ischemic brain injury

FDA issues complete response letter for sNDA of pimavanserin

Microglial EZH2 inhibition may protect against stroke damage

First patient dosed in phase II study of ABP-450 as treatment of cervical dystonia

Advaxis and Columbia University Irving Medical Center enter agreement on phase I study of ADXS-504

89bio receives FDA guidance regarding design for phase IIb ENLIVEN study of BIO89-100

Safety cohort data from phase II study of prexigebersen plus frontline therapies for AML

VIR-7831 maintains neutralizing activity against SARS-CoV-2 California variant

GPR68 targeting is protective against ischemic stroke in mice

DMC approves increased dosing frequency in phase II study of Brilacidin for COVID-19

Initial clinical data from phase I/II SWORD-1 study of TPX-0046

Positive phase I/II data for VLA-2001 COVID-19 vaccine candidate

Biotheus describes antibodies targeting carbonic anhydrase IX

Roche identifies new MAGL inhibitors

New IRAK-4 inhibitors discovered at Shanghai Institute of Materia Medica

BenevolentAI Bio patents tyrosine-protein kinase ABL1 inhibitors

Seven mostly unknown genes bring order to minimal genome cell division

New nitazoxanide derivatives synthesized at Beijing Junke Huayuan Med Tech

Ionis initiates phase III study of ION-363

FDA approves Qelbree for the treatment of ADHD in pediatric patients

Molecular discontinues development of MT-3724 to focus on next-generation ETB candidates

Azafaros initiates phase I study of AZ-3102 for rare neurogenetic disorders

First subjects dosed in study comparing nasal nalmefene with nasal naloxone

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...